135 related articles for article (PubMed ID: 6196890)
1. Treatment of 49 unrandomized patients with advanced Hodgkin's disease.
Chisesi T; Ricciardi O; Dal Fior S; Cappellari F; Pozza F; Battista R; Cortelazzo S; Capnist G; D'Emilio A; Rodeghiero F
Tumori; 1983 Oct; 69(5):463-7. PubMed ID: 6196890
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.
Piga A; Ambrosetti A; Todeschini G; Cetto G; Perona G; Cellerino R
Cancer Treat Rep; 1984; 68(7-8):947-51. PubMed ID: 6204754
[TBL] [Abstract][Full Text] [Related]
4. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP.
Santoro A; Viviani S; Villarreal CJ; Bonfante V; Delfino A; Valagussa P; Bonadonna G
Cancer Treat Rep; 1986 Mar; 70(3):343-8. PubMed ID: 2420444
[TBL] [Abstract][Full Text] [Related]
5. Pediatric Hodgkin's disease.
Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM
J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795
[TBL] [Abstract][Full Text] [Related]
6. MOPP treatment of resistant Hodgkin's disease following ABVD failure.
Cimino G; Anselmo AP; Marzullo A; Maurizi Enrici R; Mauro F; Papa G; Mandelli F
Tumori; 1983 Oct; 69(5):469-72. PubMed ID: 6196891
[TBL] [Abstract][Full Text] [Related]
7. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
8. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
9. Advanced Hodgkin's disease: ABVD is better, yet is not good enough!
Diehl V
J Clin Oncol; 2003 Feb; 21(4):583-5. PubMed ID: 12586791
[No Abstract] [Full Text] [Related]
10. Combined chemotherapy (MOPP or ABVD)-radiotherapy approach in advanced Hodgkin's disease.
Bonadonna G; Zucali R; De Lena M; Valagussa P
Cancer Treat Rep; 1977 Aug; 61(5):769-77. PubMed ID: 70270
[No Abstract] [Full Text] [Related]
11. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study.
Salloum E; Doria R; Farber LR; Roberts KB; Cooper DL
Cancer J Sci Am; 1995; 1(4):267-73. PubMed ID: 9166487
[TBL] [Abstract][Full Text] [Related]
12. Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages?
Andrieu JM; Colonna P
J Clin Oncol; 1998 Jun; 16(6):2283. PubMed ID: 9626234
[No Abstract] [Full Text] [Related]
13. Greater curability in advanced Hodgkin's disease?
Portlock CS
Cancer J Sci Am; 1999; 5(5):264-5. PubMed ID: 10526665
[No Abstract] [Full Text] [Related]
14. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
Weiner MA; Leventhal B; Brecher ML; Marcus RB; Cantor A; Gieser PW; Ternberg JL; Behm FG; Wharam MD; Chauvenet AR
J Clin Oncol; 1997 Aug; 15(8):2769-79. PubMed ID: 9256118
[TBL] [Abstract][Full Text] [Related]
15. The treatment of advanced hodgkin's disease.
Straus DJ; Lee BJ; Koziner B; Nisce LZ; Young CW; Clarkson BD
Blut; 1981 Aug; 43(2):119-24. PubMed ID: 6167303
[TBL] [Abstract][Full Text] [Related]
16. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
[TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) after failure of MOPP therapy.
Krikorian JG; Portlock CS; Rosenberg SA
Cancer; 1978 Jun; 41(6):2107-11. PubMed ID: 77716
[TBL] [Abstract][Full Text] [Related]
18. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987.
Tubiana M; Henry-Amar M; Carde P; Burgers JM; Hayat M; Van der Schueren E; Noordijk EM; Tanguy A; Meerwaldt JH; Thomas J
Blood; 1989 Jan; 73(1):47-56. PubMed ID: 2462943
[TBL] [Abstract][Full Text] [Related]
19. Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD).
Santoro A; Bonadonna G
Cancer Chemother Pharmacol; 1979; 2(2):101-5. PubMed ID: 93984
[TBL] [Abstract][Full Text] [Related]
20. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
Canellos GP
Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
